These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 16607692)
21. Safety and feasibility of breast conserving therapy in Indian women: two decades of experience at Tata Memorial Hospital. Dinshaw KA; Sarin R; Budrukkar AN; Shrivastava SK; Deshpande DD; Chinoy RF; Badwe R; Hawaldar R J Surg Oncol; 2006 Aug; 94(2):105-13. PubMed ID: 16847919 [TBL] [Abstract][Full Text] [Related]
22. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524 [TBL] [Abstract][Full Text] [Related]
24. Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy. Garassino I; Gullo G; Orefice S; Tondulli L; Masci G; Salvini P; Eboli M; Di Tommaso L; Giordano L; Alloisio M; Roncalli M; Santoro A Breast; 2009 Aug; 18(4):263-6. PubMed ID: 19682903 [TBL] [Abstract][Full Text] [Related]
25. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
26. Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories. Blancas I; Gómez FJ; Bermejo B; Hennessy BT; Chirivella I; Magro A; Caballero A; Ferrer J; Valero V; Lluch A Clin Breast Cancer; 2009 Nov; 9(4):231-6. PubMed ID: 19933078 [TBL] [Abstract][Full Text] [Related]
27. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Lyman GH; Cosler LE; Kuderer NM; Hornberger J Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307 [TBL] [Abstract][Full Text] [Related]
28. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Meijnen P; Oldenburg HS; Loo CE; Nieweg OE; Peterse JL; Rutgers EJ Br J Surg; 2007 Aug; 94(8):952-6. PubMed ID: 17440955 [TBL] [Abstract][Full Text] [Related]
29. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long? Kaufmann M; Rody A Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229 [TBL] [Abstract][Full Text] [Related]
30. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence]. Fodor J Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868 [TBL] [Abstract][Full Text] [Related]
31. Survival after treatment for breast cancer in a geographically defined population. Tejler G; Norberg B; Dufmats M; Nordenskjöld B; Br J Surg; 2004 Oct; 91(10):1307-12. PubMed ID: 15376206 [TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in node negative premenopausal women treated with breast conserving therapy without adjuvant systemic therapy. Budrukkar AN; Sarin R; Chinoy RF; Badwe R; Shrivastava SK; Dinshaw KA Breast; 2008 Jun; 17(3):263-9. PubMed ID: 18060781 [TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J; J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604 [TBL] [Abstract][Full Text] [Related]
35. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353 [TBL] [Abstract][Full Text] [Related]
36. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Parikh RR; Yang Q; Higgins SA; Haffty BG Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):35-42. PubMed ID: 17855007 [TBL] [Abstract][Full Text] [Related]
37. Postmastectomy radiotherapy in intermediate risk stage I-II breast cancer patients. Mladenovic J; Susnjar S; Gavrilovic D; Borojevic N J BUON; 2007; 12(2):215-20. PubMed ID: 17600875 [TBL] [Abstract][Full Text] [Related]
38. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382 [TBL] [Abstract][Full Text] [Related]
39. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731 [TBL] [Abstract][Full Text] [Related]
40. Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. Holli K; Hietanen P; Saaristo R; Huhtala H; Hakama M; Joensuu H J Clin Oncol; 2009 Feb; 27(6):927-32. PubMed ID: 19114687 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]